105 related articles for article (PubMed ID: 19968087)
1. [Advances in etiology and management of Castleman's disease].
Han X; Zhou DB
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):639-43. PubMed ID: 19968087
[TBL] [Abstract][Full Text] [Related]
2. The use of monoclonal antibodies to treat Castleman's disease.
Robey RC; Mletzko S; Colley C; Balachandran K; Bower M
Immunotherapy; 2014; 6(2):211-9. PubMed ID: 24491093
[TBL] [Abstract][Full Text] [Related]
3. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Lee FC; Merchant SH
Am J Hematol; 2003 May; 73(1):48-53. PubMed ID: 12701121
[TBL] [Abstract][Full Text] [Related]
4. Siltuximab: a new option for the management of Castleman's disease.
Barquero N
Drugs Today (Barc); 2015 Jan; 51(1):21-8. PubMed ID: 25685858
[TBL] [Abstract][Full Text] [Related]
5. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.
Parravicini C; Corbellino M; Paulli M; Magrini U; Lazzarino M; Moore PS; Chang Y
Am J Pathol; 1997 Dec; 151(6):1517-22. PubMed ID: 9403701
[TBL] [Abstract][Full Text] [Related]
6. [Castleman's disease, a fatal cause of lymph node enlargement and fever].
Verhave G; Lettinga KD; van de Wiel BA; Vasmel WL
Ned Tijdschr Geneeskd; 2009; 153():A485. PubMed ID: 19857312
[TBL] [Abstract][Full Text] [Related]
7. [Multicentric Castleman disease not associated with HHV-8 and HIV viruses].
Forteski Dde F; Netto FC; Lomonte AB; dos Anjos BC; Zerbini MC; Zerbini CA
Rev Bras Reumatol; 2014; 54(4):326-9. PubMed ID: 25627230
[TBL] [Abstract][Full Text] [Related]
8. Atypical cellular disorders.
McClain KL; Natkunam Y; Swerdlow SH
Hematology Am Soc Hematol Educ Program; 2004; ():283-96. PubMed ID: 15561688
[TBL] [Abstract][Full Text] [Related]
9. Hyaline vascular Castleman's disease: a case report and brief review of the literature.
van den Berge M; Pauwels P; Jakimowicz JJ; Creemers GJ
Neth J Med; 2002 Dec; 60(11):444-7. PubMed ID: 12685494
[TBL] [Abstract][Full Text] [Related]
10. Castleman's disease.
Palestro G; Turrini F; Pagano M; Chiusa L
Adv Clin Path; 1999; 3(1-2):11-22. PubMed ID: 10655569
[TBL] [Abstract][Full Text] [Related]
11. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
[TBL] [Abstract][Full Text] [Related]
12. Practical Management of Castleman's Disease.
Alzahrani MF; Radwi M; Leitch HA
Acta Haematol; 2016; 136(1):16-22. PubMed ID: 27160307
[TBL] [Abstract][Full Text] [Related]
13. Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient.
Murphy C; Hawkes E; Chionh F; Chong G
J Clin Pharm Ther; 2017 Feb; 42(1):111-114. PubMed ID: 27790727
[TBL] [Abstract][Full Text] [Related]
14. Castleman's disease. Update on pathogenesis.
Al-Maghrabi JA
Saudi Med J; 2011 May; 32(5):451-8. PubMed ID: 21556463
[TBL] [Abstract][Full Text] [Related]
15. HIV-associated multicentric Castleman's disease.
Stebbing J; Pantanowitz L; Dayyani F; Sullivan RJ; Bower M; Dezube BJ
Am J Hematol; 2008 Jun; 83(6):498-503. PubMed ID: 18260115
[TBL] [Abstract][Full Text] [Related]
16. Human herpes virus-8-associated multicentric Castleman's disease in an HIV-positive patient presenting with relapsing and remitting hyponatraemia.
Sasaki H; Maeda T; Hara Y; Osa M; Imai K; Moriguchi K; Mikita K; Fujikura Y; Kaida K; Kawana A
Int J STD AIDS; 2015 Oct; 26(12):909-11. PubMed ID: 25504830
[TBL] [Abstract][Full Text] [Related]
17. Colocalization of the viral interleukin-6 with latent nuclear antigen-1 of human herpesvirus-8 in endothelial spindle cells of Kaposi's sarcoma and lymphoid cells of multicentric Castleman's disease.
Brousset P; Cesarman E; Meggetto F; Lamant L; Delsol G
Hum Pathol; 2001 Jan; 32(1):95-100. PubMed ID: 11172301
[TBL] [Abstract][Full Text] [Related]
18. [Multicentric Castleman's disease (MCD): recent knowledge of its pathogenesis].
Higashibara M; Horie R; Yoneyama A; Mori S
Rinsho Ketsueki; 1992 Nov; 33(11):1649-60. PubMed ID: 1469779
[No Abstract] [Full Text] [Related]
19. Clinical response to liposomal doxorubicin and rituximab in HHV-8-associated multicentric Castleman's disease in an HIV-positive patient.
Osa M; Maeda T; Misawa K; Imai K; Fujikura Y; Kawana A
J Infect Chemother; 2016 Dec; 22(12):804-807. PubMed ID: 27373909
[TBL] [Abstract][Full Text] [Related]
20. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.
Carbone A; De Paoli P; Gloghini A; Vaccher E
Int J Cancer; 2015 Jul; 137(2):251-61. PubMed ID: 24771491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
